Author details

Full Name

Ricky Hsu

Affiliation

ORCID

Career Start Year

1992

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36782125	Heavily treatment-experienced people living with HIV in the OPERAÂ® cohort: population characteristics and clinical outcomes.		2023
37966701	CabotegravirÂ +Â Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort.		2023
37489298	Definition, Burden, and Predictors of HIV-Associated Wasting and Low Weight in the OPERA Cohort.		2023
35923143	Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV.	AIDS Research and Human Retroviruses	2022
34609897	Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort.	AIDS Patient Care and STDs	2021
34002626	Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States.	AIDS Research and Human Retroviruses	2021
33838004	Weight gain before and after switch from TDF to TAF in a U.S. cohort study.	Journal of the International AIDS Society	2021
33710017	To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment.	AIDS	2021
33048874	Incident type 2 diabetes mellitus after initiation of common HIV antiretroviral drugs.	AIDS	2021
33247876	Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score.	HIV Medicine	2021
33343858	Antiretroviral therapy and liver disorders in the OPERA cohort.	Therapeutic Advances in Drug Safety	2020
31985887	Validation of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) chronic kidney disease risk score in HIV-infected patients in the USA.	HIV Medicine	2020
33211670	Assessing bias introduced in estimated glomerular filtration rate by the inhibition of creatinine tubular secretion from common antiretrovirals.	Antiviral Therapy	2020
30651100	HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA observational database: a cohort study.	AIDS Research and Therapy	2019
30414209	Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.	Pharmacotherapy	2019
30546862	Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database.	Therapeutic Advances in Drug Safety	2018
27587070	Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.	Clinical Drug Investigation	2017
27984559	Psychiatric Symptoms in Patients Receiving Dolutegravir.	Journal of acquired immune deficiency syndromes (1999)	2017
23264364	Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection.	Clin Infect Dis	2013
21051598	The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.	Science	2010
19563238	Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).	AIDS Research and Human Retroviruses	2009
18771059	Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.	Antiviral Therapy	2008
17208898	Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naÃ¯ve subjects: a 48-week pilot study.	HIV Clinical Trials	2006
1482051	Genomic heterogeneity of DNA repair. Role in aging?	Annals of the New York Academy of Sciences	1992